Investigational drug · Phase 2
EVO756
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Migraine, Chronic Inducible Urticaria, Atopic Dermatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
1 still active
All registered trials
4
Any phase or sponsor naming "EVO756"
First trial start
2024
Aug 14, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EVO756", any sponsor or status.
Conditions studied
As listed on its trial records.
- Migraine
- Chronic Inducible Urticaria
- Atopic Dermatitis
- Chronic Spontaneous Urticaria
Approved drugs for the same conditions: Migraine · Atopic dermatitis (eczema) · Chronic hives (urticaria) · Neurology · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "EVO756" as an intervention, largest first.
- Study of EVO756 in Adults With MigrainePivotal-lookingRecruiting
Evommune, Inc.Industry
NCT07616128 · 330 participants (planned) · Start Jul 29, 2026 · Primary completion Oct 2027
Drug: EVO756, Dose 1; EVO756, Dose 2 and 1 more · For: Migraine
Sites: Chandler, Arizona; Buena Park, California; Fresno, California · 45 sites in all
- Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)Pivotal-lookingCompleted
Evommune, Inc.Industry
NCT06873516 · 182 participants · Start Mar 20, 2025 · Primary completion May 29, 2026
Drug: EVO756; EVO756 and 2 more · For: Chronic Spontaneous Urticaria
Sites: Birmingham, Alabama; Mobile, Alabama; Fremont, California · 53 sites in all
- Phase 2b Study of EVO756 in Adults With Atopic DermatitisPivotal-lookingCompleted
Evommune, Inc.Industry
NCT07150845 · 121 participants · Start Aug 26, 2025 · Primary completion Jul 23, 2026
Drug: EVO756; EVO756 and 2 more · For: Atopic Dermatitis
Sites: Phoenix, Arizona; Fremont, California; Los Angeles, California · 29 sites in all
Evommune, Inc.Industry
NCT06603220 · 30 participants · Start Aug 14, 2024 · Primary completion May 8, 2025
Drug: Oral EVO756 300 mg QD; Oral EVO756 50 mg BID · For: Chronic Inducible Urticaria
Sites: Birmingham, Alabama; Los Angeles, California; Sacramento, California · 18 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Beyond Omalizumab: Emerging Biologic and Small Molecule Therapies in Chronic Spontaneous Urticaria.
Kaur S, Kumaran MS, Singh S, et al. · Clin Exp Allergy 2026
- MRGPRX2 in Allergic and Immune-Mediated Diseases: Mechanisms, Clinical Relevance, and Therapeutic Translation.
Reinisch W, Li Y, Xiong P, et al. · Clin Rev Allergy Immunol 2026
Also in development for Migraine
- AXS-07meloxicam-rizatriptanPhase 31 trial
Axsome Therapeutics, Inc. · Migraine
- BHV-2100Phase 21 trial
Biohaven Therapeutics Ltd. · Migraine
- MEDI0618Phase 21 trial
AbbVie · Migraine
- MTX101Phase 21 trial
Manistee Therapeutics · Migraine
- PRT-064040Phase 21 trial
Sichuan Purity Pharmaceutical Technology Co., Ltd. · Migraine
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.